CAMP4 Therapeutics reports positive Phase 1 trial results for CMP-CPS-001, advances Parkinson's disease program, and joins Russell 2000 Index. The forward-looking statements in the press release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback